JIUYUAN GENE (02566): Jixinfen approved for market by the National Medical Products Administration.

JIUYUAN GENE (02566) announced that the injection solution of polyethylene glycol-modified human granulocyte colony stimulating factor (trademark: Jixinfen) has been approved by the National Medical Products Administration of the People's Republic of China for marketing. It is used to treat adult patients with non-myeloid malignant tumors who are at risk of developing febrile neutropenia during bone marrow suppression chemotherapy, in order to reduce the incidence of infections manifested as febrile neutropenia. Jixinfen is obtained by crosslinking and purifying human granulocyte colony stimulating factor (hG-CSF) with 20KD polyethylene glycol, resulting in a significantly prolonged half-life, enhanced biological stability, resistance to enzyme degradation, reduced immunogenicity and antigenicity, and reduced likelihood of developing neutralizing antibodies. Polyethylene glycol-modified human granulocyte colony stimulating factor (PEG-hG-CSF) only needs to be administered once per chemotherapy cycle, improving patient compliance and ensuring the safety and effectiveness of the chemotherapy regimen.